High Alert
Contraindicated in:
Use Cautiously in:
Structural heart disease, concurrent diuretic use, hypokalemia, hypomagnesemia, history of arrhythmia/syncope, or other risk factors for arrhythmias
;CV: hypotension, bradycardia,
QT interval prolongation
, TORSADES DE POINTESDerm: flushing, sweating
EENT: blurred vision, diplopia, miosis
Endo: adrenal insufficiency
GI: constipation, nausea, vomiting
Neuro: confusion, sedation, dizziness, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams
Resp: RESPIRATORY DEPRESSION (INCLUDING CENTRAL SLEEP APNEA AND SLEEP-RELATED HYPOXEMIA)
Misc: allodynia, opioid-induced hyperalgesia,
physical dependence
,psychological dependence
, toleranceDrug-drug:
Use with extreme caution with any drug known to potentially prolong QT interval, including class I and III antiarrhythmics, some neuroleptics and tricyclic antidepressants, and calcium channel blockers
.CYP3A4 inhibitors, CYP2C9 inhibitors, CYP2C19 inhibitors, or CYP2D6 inhibitors, including ritonavir, ketoconazole, itraconazole, fluconazole, clarithromycin, erythromycin, nefazodone, diltiazem, verapamil, nelfinavir, fosamprenavir, and fluvoxamine, ↑ levels and risk of opioid toxicity; careful monitoring during initiation, dose changes, or discontinuation of the inhibitor is recommended.
CYP3A4 inducers, CYP2C9 inducers, or CYP2C19 inducers, including barbiturates, carbamazepine, efavirenz, corticosteroids, modafinil, nevirapine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, or rifampin, may ↓ levels and analgesia; if inducers are discontinued or dosage ↓, patients should be monitored for signs of opioid toxicity and necessary dose adjustments should be made.
Use with benzodiazepines or other CNS depressants, including other opioids, nonbenzodiazepine sedative/hypnotics, anxiolytics, general anesthetics, muscle relaxants, antipsychotics, and alcohol, may cause profound sedation, respiratory depression, coma, and death; reserve concurrent use for when alternative treatment options are inadequate.
Drug-Natural Products:
Moderate to Severe Pain
Opioid Detoxification
Absorption: 50% absorbed following oral administration. IV administration results in complete bioavailability.
Distribution: Widely distributed to tissues.
Protein Binding: 8590%.
Half-Life: 1525 hr (↑ with chronic use).
(analgesic effect)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | 3060 min | 90120 min | 412 hr |
IM, IV, SUBQ | 1020 min | 60120 min | 812 hr |
Inform patient of the potential for arrhythmias and emphasize the importance of regular ECGs.
NDC Code